DarshanTalks Podcast

The Hidden Legal Risks of AI Sponsor Protocols

03 Apr 2026

Contributed by Lukas

Send us Fan Mail Is AI the savior of clinical research costs, or a ticking time bomb for data integrity? In this episode, Darshan Kulkarni dives into...

The $100M Mistake: Why AI-Generated Drugs May Not Be Patentable

02 Apr 2026

Contributed by Lukas

Send us Fan Mail"The model said so" is not a defense. In the rush to integrate AI into drug discovery, life science companies are sprinting ...

Is AI replacing your Doctor?

30 Mar 2026

Contributed by Lukas

Send us Fan MailIn this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni explores the unsettling transition from "Googling ...

Why the OIG Just Revolutionized Pharma Marketing (And What It Costs You)

28 Mar 2026

Contributed by Lukas

Send us Fan Mail On January 27, 2026, the HHS Office of Inspector General (OIG) changed the game for pharmaceutical manufacturers. In a landmark Spec...

6 Categories of "Bulk Data" That Could Land You in Federal Court.

27 Mar 2026

Contributed by Lukas

Send us Fan MailThe DOJ just changed the rules of the game for the Life Sciences industry. As of January 2025, transferring "Bulk Sensitive Perso...

The Utah Experiment: The Dangerous New Frontier of AI Prescribing

26 Mar 2026

Contributed by Lukas

Send us Fan MailIs your state "sandbox" a playground or a legal minefield? In this episode, Darshan Kulkarni—pharmacist and attorney—dis...

Is Your DTC Program a Kickback Trap?

23 Mar 2026

Contributed by Lukas

Send us Fan Mail The OIG has officially shifted the goalposts for Direct-to-Consumer (DTC) and Direct-to-Patient (DTP) programs. For years, federal h...

The Hidden Death Sentence for Trial Sites

20 Mar 2026

Contributed by Lukas

Send us Fan Mail In this episode of KLF Deep Dive, Darshan Kulkarni uncovers the catastrophic risks clinical trial sites face when they fail to vet t...

FDA "Screams": The Real Reason Your Snack Is At Risk

19 Mar 2026

Contributed by Lukas

Send us Fan MailUndeclared allergens remain the #1 cause of food recalls in the U.S., yet many brands still treat labeling as a "marketing" ...

2 Laws More Dangerous Than HIPAA for Patient Engagement

16 Mar 2026

Contributed by Lukas

Send a text Think HIPAA is your biggest hurdle in pharma marketing? Think again. In this episode of KLF Deep Dive, Darshan Kulkarni reveals why focus...

"Invite-Only" Compliance Is Over: Is Your Cosmetic Company Ready?

14 Mar 2026

Contributed by Lukas

Send a text The "handshake" era of cosmetic compliance is officially over. Under new authorities in Sections 605, 610, and 704, the FDA has...

Audit-Proof Your Site: The Training Gap Killing Your Contracts

13 Mar 2026

Contributed by Lukas

Send a text In clinical research, if it isn't documented, it never happened. Many site owners mistake a competent team for a compliant one—a m...

15 Years in Prison for Marketing Fraud

12 Mar 2026

Contributed by Lukas

Send a textIs your marketing team building a brand or a federal case? In this episode, we deconstruct the $1.2 billion collapse of Boom Care. What lo...

Is your "Clinical Decision Support" tool actually an unregulated medical device?

11 Mar 2026

Contributed by Lukas

Send a textIn January 2026, the FDA sharpened the line between helpful software and regulated medical devices. If your AI sits inside an EHR, providin...

The FDA’s New Political Enforcement Strategy

10 Mar 2026

Contributed by Lukas

Send a textIn this episode, Darshan Kulkarni exposes a massive legal shift that is quietly dismantling the "Practice of Medicine" defense. W...

Why Your "Physician-Only" Ads Aren't Safe from Regulators

09 Mar 2026

Contributed by Lukas

Send a text In this episode of the KLF Deep Dive, Darshan Kulkarni sits down with Phyllis Marcus, Vice President of the National Advertising Division...

The Messy Reality of AI Prescriptions

08 Mar 2026

Contributed by Lukas

Send a textState governments are racing to innovate by allowing AI to renew and improve prescriptions—but are they walking into a federal trap? In t...

Why Your Consultant’s Report Is a Legal Liability

07 Mar 2026

Contributed by Lukas

Send a textIn the high-stakes world of Life Science M&A, hiring expert consultants for GXP, IT, and data privacy is standard operating procedure. ...

Stop Reporting Results? The NIH’s "Get Out of Jail Free" Card

06 Mar 2026

Contributed by Lukas

Send a text The NIH just dropped a regulatory bombshell: Notice NOT-OD-26-032. Effectively immediately, Basic Experimental Studies in Humans (BESH) a...

Final LGBTQ Individuals in clinical research

05 Mar 2026

Contributed by Lukas

Send a textSupport the showwww.kulkarnilawfirm.com

When the FDA Plays Politics

04 Mar 2026

Contributed by Lukas

Send a textIn this episode of KLF Deep Dive, we examine a chilling shift in regulatory enforcement: the weaponization of "Intended Use." If ...

Your Site’s Background Check is Illegally Incomplete - Here is why

03 Mar 2026

Contributed by Lukas

Send a textIn this episode, Darshan Kulkarni dives into the terrifying reality of compliance failures at clinical trial sites. While most directors wo...

Is Your Off-Label Use Now a Federal Crime?

02 Mar 2026

Contributed by Lukas

Send a textFor decades, a "clean mental line" existed: Doctors prescribe, and companies don't promote off-label. That line just got a l...

Futurist Bruce McCabe: How Narrow AI is Solving Healthcare’s Biggest Problems

23 Feb 2026

Contributed by Lukas

In this episode, we sit down with world-renowned futurist Bruce McCabe to cut through the hype of large language models like ChatGPT and explore the &...

The Battle Over Weight Loss and Compounded Drugs

16 Feb 2026

Contributed by Lukas

In this episode of DarshanTalks, host and attorney-pharmacist Darshan Kulkarni deconstructs the legal "scorched-earth" offensive currently r...

Why Cosmetic Ingredient Names Matter and What MOCRA Really Means - Interview with Heather Bustos

29 Jan 2026

Contributed by Lukas

In this episode, I sit down with FDA compliance attorney Heather Butos to unpack two topics most cosmetic pros ignore until it’s too late: INCI (ing...

Compliance Isn’t a Deal Killer… Until It Is - Interview with Stephanie Trunk

22 Jan 2026

Contributed by Lukas

Life sciences M&A is picking up again, but today’s deals look nothing like they did two years ago.In this episode, Darshan Kulkarni sits down wi...

Cosmetic ingredients the FDA doesn’t want you to use

17 Jan 2026

Contributed by Lukas

A brief discussion on the various cosmetic ingredients used by cosmetic manufacturers and the concerns FDA has recently found as a result of their own...

Why Federal Agencies Are Targeting Executives

15 Jan 2026

Contributed by Lukas

Federal enforcement is changing. Regulators aren’t just going after companies anymore. They’re naming CEOs, CMOs, heads of clinical, quality, and ...

Why the New Food Pyramid Matters to You

10 Jan 2026

Contributed by Lukas

 Everyone’s talking about the new food pyramid like it’s diet advice. I’m here to tell you it’s regulatory policy in disguise. In this episod...

Ex FDA Commissioner Robert Califf on FDA Authority, Politics, and the Health Crisis No One Wants to Name

08 Jan 2026

Contributed by Lukas

Episode DescriptionIn this episode, Darshan Kulkarni sits down with former FDA Commissioner Robert Califf for a wide-ranging conversation on FDA autho...

Buying a Med Spa? GLP-1 Compliance Can Kill the Deal

08 Jan 2026

Contributed by Lukas

GLP-1 weight loss programs are everywhere right now, especially in the med spa space. For M&A lawyers and deal teams, that popularity comes with s...

New crown jewel valuing patient data

02 Jan 2026

Contributed by Lukas

For decades, biotech M&A followed a familiar script. Patents drove value. Molecules closed deals.That script is breaking.In today’s precision me...

Your Staff is trained, but can you prove it?

26 Dec 2025

Contributed by Lukas

Staffing and training are not just operational issues. They are inspection risks. In this episode, we break down what sponsors and regulators actually...

What Happens When a Sponsor Walks Away Early?

23 Dec 2025

Contributed by Lukas

 Early termination by a sponsor can leave a clinical research site holding the bill for prep work, fees, and staffing. In this episode, Darshan expla...

Cosmetic Claims the FDA Hates

22 Dec 2025

Contributed by Lukas

Your skincare product may look like a cosmetic, but one wrong claim can legally turn it into an unapproved drug.In this episode of KLF Deep Dive, we b...

Biggest Legal Mistakes in Influencer Marketing

18 Dec 2025

Contributed by Lukas

Influencers can boost visibility fast, but they also create real regulatory exposure if they go off script. The FTC requires influencers to clearly di...

Your Mood, Energy, and Sleep Claims Might Be Regulated

11 Dec 2025

Contributed by Lukas

 A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing oft...

Device Fail: The Legal Anatomy of a Faulty Implant Scandal

10 Dec 2025

Contributed by Lukas

 A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selli...

5 Documents the FDA Will Demand on Site — Are You Ready?

09 Dec 2025

Contributed by Lukas

In this episode of DarshanTalks, you dive into what U.S. Food and Drug Administration (FDA) inspectors will demand when they show up on-site. You walk...

Cosmetic Marketing Mistakes That Trigger Regulators

04 Dec 2025

Contributed by Lukas

 Beauty brands hit trouble when they forget they’re dealing with two regulators, not one. The FDA controls how cosmetics are labeled and when a cla...

Why Your Clinical Trial Contract Is Leaving Cash on the Table

02 Dec 2025

Contributed by Lukas

Clinical research sites lose money when sponsor contracts skip the real costs of running a study. In this episode, Darshan breaks down how to protect ...

Why Testimonials Can Get Your Brand Sued

29 Nov 2025

Contributed by Lukas

Before-and-after photos and glowing testimonials can sell products fast, but they’re also some of the most heavily scrutinized tools in advertising....

How to Get Sponsors to Pay Faster than Net 90

27 Nov 2025

Contributed by Lukas

 Can I negotiate faster payment terms so I don't run out of cash flow? Many sponsor contracts set 90 to 120 day payment timelines. This, however...

Pharma merger killers

14 Nov 2025

Contributed by Lukas

Darshan Kulkarni explores why compliance isn’t just a side issue—it’s often the ultimate dealbreaker in pharma and biotech transactions.When buy...

Balance FDA Rules with FTC Advertising Requirements

12 Nov 2025

Contributed by Lukas

Brands often struggle to balance FDA cosmetic rules with FTC advertising standards. The FDA oversees labeling and determines whether a product is a co...

Key Clauses in PI Contracts to Review

10 Nov 2025

Contributed by Lukas

Many clinical trial site leaders overlook critical risks hidden in physician employment agreements. These contracts often contain clauses that can exp...

Compliance guru talks practical Insights on Speaker Programs

07 Nov 2025

Contributed by Lukas

In this episode, host Darshan Kulkarni speaks with Joseph Keeney about speaker programs in the life sciences industry, exploring practical differences...

Trends in Small Life Sciences Transactions

05 Nov 2025

Contributed by Lukas

Darshan Kulkarni in conversation with Nella Bloom, for an in-depth discussion on the current state of small business transactions, private equity tren...

Protect Your Site If a Sponsor Terminates Early

03 Nov 2025

Contributed by Lukas

When sponsors terminate a clinical trial early, research sites may face financial losses for preparatory or ongoing work. To mitigate this risk, contr...

Are Pharma Chatbots Putting You at Regulatory Risk?

01 Nov 2025

Contributed by Lukas

Pharmaceutical chatbots are increasingly used to answer patient drug questions, but they carry significant regulatory and compliance risks. While the ...

Are Your Cosmetic Company Records Ready for FDA Audits?

30 Oct 2025

Contributed by Lukas

Companies must maintain thorough records to meet FDA inspection requirements, including safety substantiation files, labeling proofs, ingredient docum...

When Medical Affairs Becomes Commercial in Disguise

24 Oct 2025

Contributed by Lukas

Darshan explores a critical question for life sciences companies: is your medical affairs team truly independent from commercial—or are you just pre...

Serious Adverse Event Reporting Under MoCRA

22 Oct 2025

Contributed by Lukas

Under the Modernization of Cosmetics Regulation Act (MoCRA), reporting serious adverse events to the FDA is now mandatory. Companies must report serio...

Key SOPs for Clinical Trials

20 Oct 2025

Contributed by Lukas

Darshan Kulkarni highlights that to stay compliant with the FDA, companies don’t need an exhaustive set of SOPs—just the essential ones. Inspector...

Payer Presentations Can Trigger Enforcement

18 Oct 2025

Contributed by Lukas

The boundary between scientific exchange and marketing in payer presentations is increasingly blurred, creating significant compliance and enforcement...

Pharmacies v manufacturers

16 Oct 2025

Contributed by Lukas

In this episode, Darshan Kulkarni speaks with Dae Lee about the growing conflict between pharmaceutical manufacturers and pharmacy benefit managers (P...

Is Clinical Research Ready for the new FDA?

13 Oct 2025

Contributed by Lukas

The FDA has criticized the industry for not taking advertising and promotion seriously and is now cracking down, as evidenced by hundreds of non-compl...

Is your cosmetics company FDA-registered?

11 Oct 2025

Contributed by Lukas

Cosmetics companies must now register both their facilities and products with the FDA under the new MoCRArequirements, a shift from the previous volun...

Will AI Replace Doctors in clinical research?

09 Oct 2025

Contributed by Lukas

Darshan discusses the potential role of AI in medicine. He believes fears of AI replacing doctors for diagnosis are currently overblown, as trust in p...

Risks in Direct-to-Patient Engagement

07 Oct 2025

Contributed by Lukas

Direct-to-Patient (DTP) models are transforming how medications reach patients, moving beyond clinical research into commercial distribution. Original...

Inside 340B: Challenges, Controversies, and Opportunities

01 Oct 2025

Contributed by Lukas

Darshan Kulkarni speaks with Thomas Siepka, CEO of HCI Healthcare Consultants, to take a deep dive into the often-misunderstood world of the 340B drug...

IRBs in 2025: What’s Really Changing?

27 Sep 2025

Contributed by Lukas

In this conversation, Edye Edens with Nyssa Towsley from UNLV, examine how today’s shifting funding landscape is reshaping IRB operations. Historica...

3 Red Flags in Telemedicine Partnerships

25 Sep 2025

Contributed by Lukas

In this video, Darshan discusses recent enforcement trends show three weak spots to watch:Encounter Quality – If prescribers are just checking boxes...

What do PBMs do?

21 Sep 2025

Contributed by Lukas

In this episode, Darshan Kulkarni talks with Thomas Siepka about the 340B program, rebates, and the crucial role of pharmacy benefit managers (PBMs) i...

How AMCs Build Stronger Compliance Cultures Together

19 Sep 2025

Contributed by Lukas

 In the episode of a new series on academic medical centers, Edye Edens of Kulkarni Law Firm sits down with Cortni Romaine of Florida Atlantic Univer...

How One DME Scheme Cost Medicare $61 Million

15 Sep 2025

Contributed by Lukas

In one of the largest recent Medicare fraud cases, Peter Roussonicolos, a Florida durable medical equipment (DME) company owner, was sentenced to 12 y...

FDA to Step Up Enforcement on Pharma Advertising

12 Sep 2025

Contributed by Lukas

The FDA has recently stepped up its enforcement of pharmaceutical advertising rules, issuing 100 cease-and-desist notices and thousands of letters. Th...

Top 5 Factors Determining AMC Funding

09 Sep 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens launch an exciting new episode, focusing on the unique challenges academic medical centers (AMCs) face in securing fun...

New Series Drop: Exploring AMCs in Clinical Research

06 Sep 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens are kicking off a brand-new video series diving into the unique world of academic medical centers (AMCs) in clinical r...

Why Choose a Licensed Attorney Over a Consultant?

04 Sep 2025

Contributed by Lukas

Edye Edens and Darshan Kulkarni share the origin story of KLF and explain what makes working with licensed attorneys different from hiring non-legal c...

Marketing Problems by Hims & Hers and Lilly

02 Sep 2025

Contributed by Lukas

Telehealth and pharma are facing some of their biggest compliance challenges yet—and the latest enforcement actions prove regulators aren’t slowin...

Should Sponsors Share Site Feedback?

29 Aug 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens examine whether sponsors should provide feedback to clinical trial sites on why they were selected—or not—for a st...

AI Marketing Playbook for Drug Companies

26 Aug 2025

Contributed by Lukas

AI is no longer a distant concept in pharma marketing—it’s here, transforming campaign design, review, and distribution. CEOs and CMOs face a crit...

Should Sites Be Ready on Standby?

23 Aug 2025

Contributed by Lukas

Edye Edens and Darshan Kulkarni from KLF discuss the pros and cons for clinical trial sites considering becoming backup sites. Key points include:Spon...

Eastern District of PA Targets Pharmacies

21 Aug 2025

Contributed by Lukas

The Eastern District of Pennsylvania has ramped up False Claims Act enforcement against pharmacies, with cases ranging from multi-million dollar settl...

Telehealth Done Right

18 Aug 2025

Contributed by Lukas

The Office of Inspector General (OIG) recently issued an advisory opinion approving a telehealth business model where a management company leases clin...

DOJ and HHS Launch FCA Fraud Task Force

15 Aug 2025

Contributed by Lukas

In Fiscal Year 2024, whistleblower cases reached an all-time high of 979, signaling increased scrutiny of healthcare fraud. Just days after announcing...

Should Sponsors Cover Malpractice Insurance?

13 Aug 2025

Contributed by Lukas

Darshan and Edye tackle a hot topic in clinical research budgeting: Should malpractice insurance be considered an overhead cost that sponsors cover?E...

Instagram Post that Sparked FDA Warning Letter

11 Aug 2025

Contributed by Lukas

In this episode, Darshan Kulkarni unpacks the May 29, 2025 FDA Warning Letter issued to Sprout Pharmaceuticals. The trigger? A promotional Instagram p...

Why Are So Many Doctors Getting Arrested?

09 Aug 2025

Contributed by Lukas

Why are headlines suddenly filled with stories of doctors, nurses, healthcare executives—and even accountants—being arrested for fraud? In this ex...

How to Run Compliant Pharma Speaker Programs

06 Aug 2025

Contributed by Lukas

What really happens behind the scenes of pharmaceutical speaker programs—and why should smaller pharma companies care? In this episode of DarshanTal...

​​Are You Picking the Wrong KOLs?

04 Aug 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens tackle the complexities of identifying and working with Key Opinion Leaders (KOLs) in clinical research. While KOLs ca...

How KLF’s Client Base Evolved Over 20 Years

02 Aug 2025

Contributed by Lukas

Edye Edens interviews Darshan Kulkarni about the evolution of the Kulkarni Law Firm (KLF). Darshan reflects on how he originally envisioned working wi...

FDA Pushback on Accelerated Gene Therapy Approvals

31 Jul 2025

Contributed by Lukas

In this episode, Edye Edens dives into the FDA’s evolving scrutiny of accelerated approvals in gene therapy and rare diseases. Using the example of ...

Your DEI Program Could Trigger an FCA Case

30 Jul 2025

Contributed by Lukas

Darshan Kulkarni breaks down the Department of Justice’s new Civil Rights Fraud Initiative, launched on May 19, 2025, and why it should be on the ra...

Teva’s Charity Partnership Scrutinized

28 Jul 2025

Contributed by Lukas

A recent $425 million settlement involving Teva Pharmaceuticals highlights the legal and ethical risks charities face when partnering with pharmaceuti...

Is There a “Right” Way to Calculate FMV?

25 Jul 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens take a deep dive into one of clinical research’s most persistent questions: how is fair market value (FMV) actually ...

Can Non-Physicians Own Clinical Trial Sites?

23 Jul 2025

Contributed by Lukas

Can non-physicians own independent clinical trial sites? The answer isn’t as simple as it seems. In most states, including Texas, engaging in clinic...

The KLF Story You Haven’t Heard

20 Jul 2025

Contributed by Lukas

In this special episode, Senior Attorney Edye Edens sits down with Darshan Kulkarni, founder and principal of the Kulkarni Law Firm, for a personal an...

Why Telehealth Platforms Are Getting Sued

17 Jul 2025

Contributed by Lukas

We explore the growing wave of class action lawsuits hitting the telehealth industry—and why legal counsel, especially those advising telemedicine p...

Should Clinical Trial Sites Be Paid Differently?

15 Jul 2025

Contributed by Lukas

In this episode of the KLF Deep Dive, Darshan Kulkarni and Edye Edens engage in a practical discussion around one of the most debated issues in clinic...

How to Build an AI Compliance Program

14 Jul 2025

Contributed by Lukas

In this episode of KLF Deep Dive, Darshan Kulkarni explores the growing urgency for in-house counsel to develop AI compliance programs as artificial i...

What the Big Beautiful Bill Means for Trial Sites

11 Jul 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens examine the far-reaching implications of the newly passed “Big Beautiful Bill”—a sweeping piece of legislation t...

Co-Pay Mistakes Can Trigger DOJ Action

09 Jul 2025

Contributed by Lukas

In Alvarez v. Lincare, the Eleventh Circuit highlighted a growing risk for pharma marketers and legal teams running Direct-to-Patient (DTP) campaigns....

NIH Grant Denials Ruled Discriminatory?

08 Jul 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens break down a recent federal court ruling that challenges the NIH’s decision to halt grant funding for projects focus...

Are Speaker programs supposed to be salesy?

04 Jul 2025

Contributed by Lukas

Pharmaceutical speaker programs come in two forms: one aimed at promoting a product, and another focused purely on education. Both must be compliant, ...

DTP Compliance Just Got Tricky

28 Jun 2025

Contributed by Lukas

The Seventh Circuit just issued a pivotal decision in U.S. v. Sorenson, reshaping how pharmaceutical and medical device companies should think about d...

Should You Use AI to Draft Informed Consent?

26 Jun 2025

Contributed by Lukas

Darshan Kulkarni and Edye Edens discuss the potential and pitfalls of using AI—like ChatGPT—to draft informed consent documents in clinical resear...

Could You Survive a Surprise Pharmacy Audit?

23 Jun 2025

Contributed by Lukas

Imagine you're filling a script when a State Board of Pharmacy inspector walks in—no warning, just a clipboard and serious consequences. Most c...